# Alzheimer's Breakthroughs: At-Home Injections Arrive!

Newsy: Alzheimer’s News Weekly
Published: 2025-10-09T15:00:00.348Z
Source: https://newsyai.com/edition/bd3147ea-ba3e-44ff-96fd-9d359e97b0ed
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# The Alzheimer’s Treatment Briefing
Weekly roundup of the most important developments in Alzheimer’s care and research  
Coverage period: October 3–9, 2025 (U.S.)

—

## Top stories (ranked)

1) Leqembi at‑home injections are now shipping in the U.S., with price and support details clarified
- What’s new  
  - As of Monday, October 6, Eisai/Biogen began U.S. distribution of Leqembi IQLIK, the once‑weekly, at‑home autoinjector used after completing the initial 18‑month IV phase. The companies also launched “Leqembi Companion,” which offers nurse coaching for first injections and an app to track doses. Official launch materials confirm practical details for clinics and families. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-us-availability-leqembir-iqliktm?utm_source=openai))  
  - Reporting around the FDA’s August approval also spelled out the list price for the autoinjector—$19,500 per year—and reminded patients that Medicare Part B typically covers 80% (after the deductible), with out‑of‑pocket costs depending on supplemental coverage. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))
- Why this matters  
  - Easier dosing can keep more people on treatment. Fewer infusion visits and hands‑on coaching may reduce drop‑offs. The safety picture doesn’t change—regular MRIs and symptom watching still apply—so having the logistics, cost, and support laid out is key for families making decisions now. ([media-us.eisai.com](https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease?utm_source=openai))

2) “Repair-the-filter” Alzheimer’s shot keeps making headlines—what the new coverage adds (and what it doesn’t)
- What’s new  
  - Several outlets this week amplified a peer‑reviewed mouse study showing a nanoparticle “repair shot” that restores the brain’s protective filter (the blood‑brain barrier) and speeds the brain’s own trash removal, with quick drops in amyloid and memory gains in mice. The fresh coverage reiterates the core finding and places it in accessible language. ([nypost.com](https://nypost.com/2025/10/06/health/nanotech-used-to-reverse-alzheimers-disease-in-mice-study/?utm_source=openai))
- Why this matters  
  - It spotlights a different target: brain blood vessels and waste‑clearance, not just plaques. If it proves safe and helpful in people, it could pair with today’s plaque‑clearing drugs. But it’s still early—so far only in animals—so families should view this as a promising idea to watch, not a near‑term option. ([nypost.com](https://nypost.com/2025/10/06/health/nanotech-used-to-reverse-alzheimers-disease-in-mice-study/?utm_source=openai))

3) Practical billing/operations updates took effect October 1 that can affect memory‑clinic workflows
- What’s new  
  - Medicare’s quarterly HCPCS update for October 2025 went live, and regional Medicare contractors posted their October code change reminders. While not Alzheimer’s‑specific, these routine updates are what clinics use to turn care plans (IV maintenance, imaging, genetic tests ordered to guide anti‑amyloid use) into claims. Staying current reduces denials and delays for patients. ([hhs.gov](https://www.hhs.gov/guidance/document/october-2025-healthcare-common-procedure-coding-system-hcpcs-quarterly-update-reminder?utm_source=openai))
- Why this matters  
  - For families, this is behind‑the‑scenes—but it can decide how fast a new maintenance plan (monthly IV Leqembi, or the switch to the home autoinjector) actually starts and what bills look like. Asking your clinic’s financial counselor to confirm codes and prior auth steps can prevent surprises. ([hhs.gov](https://www.hhs.gov/guidance/document/october-2025-healthcare-common-procedure-coding-system-hcpcs-quarterly-update-reminder?utm_source=openai))

—

## What this means in plain language

- Home shots are truly here. If you or a loved one finished the first 18 months of IV Leqembi, you can now talk to your clinic about weekly at‑home injections and the new nurse‑support tools. You’ll still need MRIs and symptom checks; the “how” of dosing is easier, the “safety watch” remains the same. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-us-availability-leqembir-iqliktm?utm_source=openai))  
- New science is widening the lens. The buzzed‑about “repair shot” in mice focuses on fixing the brain’s cleanup system, not just clearing plaque. It’s not a patient option yet, but it hints at future combination approaches that treat both the “trash” and the “plumbing.” ([nypost.com](https://nypost.com/2025/10/06/health/nanotech-used-to-reverse-alzheimers-disease-in-mice-study/?utm_source=openai))  
- Paperwork matters. Medicare’s October code refresh sounds dry, but it’s how clinics get you scheduled, scanned, and treated without billing hiccups. A quick benefits check before changing dosing plans can save headaches. ([hhs.gov](https://www.hhs.gov/guidance/document/october-2025-healthcare-common-procedure-coding-system-hcpcs-quarterly-update-reminder?utm_source=openai))

—

## Quick guidance for patients and caregivers this week

- If considering the Leqembi autoinjector:  
  - Ask your clinic to update your monitoring plan (when MRIs happen after switching to home shots). ([media-us.eisai.com](https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease?utm_source=openai))  
  - Request nurse‑guided injection training and use the tracking app offered through Leqembi Companion. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-us-availability-leqembir-iqliktm?utm_source=openai))  
  - Clarify costs: list price is $19,500/year for the autoinjector; most people with Medicare Part B pay 20% after the deductible unless they have supplemental coverage that reduces it. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-injectable-version-eisai-biogens-alzheimers-drug-2025-08-29/?utm_source=openai))

- If you see “Alzheimer’s reversed in mice” headlines:  
  - It’s exciting but preliminary. Watch for announcements of human safety trials before expecting timelines for patients. ([nypost.com](https://nypost.com/2025/10/06/health/nanotech-used-to-reverse-alzheimers-disease-in-mice-study/?utm_source=openai))

—

Want us to track anti‑tau drugs, GLP‑1s (Ozempic/Wegovy), brain‑shuttle antibodies like trontinemab, vaccines, or prevention trials in future editions? Tell us what to add to the watchlist.
